RISPERIDEX 3 MG

Land: Israel

Sprog: engelsk

Kilde: Ministry of Health

Køb det nu

Indlægsseddel Indlægsseddel (PIL)
10-11-2020

Aktiv bestanddel:

RISPERIDONE

Tilgængelig fra:

DEXCEL PHARMA TECHNOLOGIES LTD

ATC-kode:

N05AX08

Lægemiddelform:

TABLETS

Sammensætning:

RISPERIDONE 3 MG

Indgivelsesvej:

PER OS

Recept type:

Required

Fremstillet af:

DEXCEL LTD, ISRAEL

Terapeutisk gruppe:

RISPERIDONE

Terapeutisk område:

RISPERIDONE

Terapeutiske indikationer:

Risperidone is indicated for the management of schizophrenia and manifestation of psychotic disorders. The antipsychotic efficacy of Risperidone was established in short-term (6 to 8-weeks) controlled trials of schizophrenic inpatients. Risperidone is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Risperidone is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe Alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. Conduct and other disruptive disorders: Treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment-requiring behavioral disorders with reduced or substandard intelligence. Treatment should not be given to children under the age of 5 years.Risperidone is indicated for the treatment of mania in bipolar disorder. These episodes are characterized by symptoms such as elevated, expansive or irritable mood, inflated self-esteem, decreased need for sleep, pressured speech, racing thoughts, distractibility, or poor judgment, including disruptive or aggressive behaviors

Autorisation dato:

2021-05-31

Dokumenter på andre sprog

Indlægsseddel Indlægsseddel arabisk 10-11-2020
Indlægsseddel Indlægsseddel hebraisk 23-05-2019

Søg underretninger relateret til dette produkt